Literature DB >> 25100841

High eomesodermin expression among CD57+ CD8+ T cells identifies a CD8+ T cell subset associated with viral control during chronic human immunodeficiency virus infection.

Federico Simonetta1, Stéphane Hua2, Camille Lécuroux2, Sandie Gérard2, Faroudy Boufassa3, Asier Sáez-Cirión4, Gianfranco Pancino4, Cécile Goujard5, Olivier Lambotte6, Alain Venet2, Christine Bourgeois7.   

Abstract

During HIV infection, increased CD57 expression among CD8(+) T cells has been associated with immune senescence and defective immune responses. Interestingly, CD57-expressing CD8(+) T cells exhibit a dual profile, being simultaneously highly cytotoxic (terminally differentiated effectors) and poorly proliferative (replicative senescent). Recent publications point toward a positive role of CD57-expressing CD8(+) T cell subsets, presumably due to their high cytolytic activity. We further investigated the phenotype of CD57-expressing CD8(+) T cells in healthy donors and during HIV infection combining CD57 expression to Eomesodermin (EOMES), a T box transcription factor which determines, coordinately with T-bet, effector and memory CD8(+) T cell differentiation. We defined in healthy donors two functionally distinct CD57-expressing CD8(+) T cell subsets exhibiting different levels of EOMES expression: EOMES(hi) CD57(+) and EOMES(int) CD57(+) CD8(+) T cells. EOMES(hi) CD57(+) cells exhibited low cytotoxic activity but preserved proliferative capacity and interleukin 7 (IL-7) receptor expression, whereas EOMES(int) CD57(+) cells exhibited obvious cytotoxic functions and a more terminally differentiated phenotype. We next performed a similar analysis in different contexts of HIV infection: primary infected patients, long-term viremic patients, aviremic patients treated with antiretroviral therapy, and HIV controllers; we demonstrated a higher percentage of CD57-expressing cells in all HIV-infected patients regardless of virological status. When heterogeneity in EOMES expression among CD57 cells was taken into account, we detected significantly higher proportions of EOMES(hi) CD57(+) cells among HIV-specific and nonspecific CD8(+) T cells from HIV controllers than in aviremic antiretroviral-treated patients and viremic patients. Importantly, such a peculiar non-terminally differentiated EOMES(hi) CD57(+) phenotypic profile was associated with viral control. Importance: This study demonstrates that functional heterogeneity exists among CD57-expressing CD8 T cells, which include both terminally differentiated, highly cytotoxic EOMES(int) CD57(+) CD8(+) T cells and less differentiated EOMES(hi) CD57(+) CD8 T cells, which do not exhibit immediate cytotoxic functions but present high proliferative capacity. Interestingly, HIV controllers present a high proportion of EOMES(hi) CD57 cells among CD57-expressing HIV-specific CD8 T cells compared to both long-term viremic and aviremic antiretroviral therapy (ART)-treated patients, suggesting a beneficial role for this cell subset in viral control.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25100841      PMCID: PMC4178742          DOI: 10.1128/JVI.02013-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

2.  Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors.

Authors:  Mathias Lichterfeld; Danlei Mou; Thai Duong Hong Cung; Katie L Williams; Michael T Waring; Jinghe Huang; Florencia Pereyra; Alicja Trocha; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker; Xu G Yu
Journal:  Blood       Date:  2008-08-26       Impact factor: 22.113

Review 3.  Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells.

Authors:  R Tarazona; O DelaRosa; C Alonso; B Ostos; J Espejo; J Peña; R Solana
Journal:  Mech Ageing Dev       Date:  2000-12-20       Impact factor: 5.432

4.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.

Authors:  Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection.

Authors:  Sulggi A Lee; Elizabeth Sinclair; Vivek Jain; Yong Huang; Lorrie Epling; Mark Van Natta; Curtis L Meinert; Jeffrey N Martin; Joseph M McCune; Steven G Deeks; Michael M Lederman; Frederick M Hecht; Peter W Hunt
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

6.  Antigen-driven effector CD8 T cell function regulated by T-bet.

Authors:  Brandon M Sullivan; Amy Juedes; Susanne J Szabo; Matthias von Herrath; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

7.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

8.  The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression.

Authors:  Pratip K Chattopadhyay; Michael R Betts; David A Price; Emma Gostick; Helen Horton; Mario Roederer; Stephen C De Rosa
Journal:  J Leukoc Biol       Date:  2008-10-10       Impact factor: 4.962

9.  Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.

Authors:  Andrew M Intlekofer; Naofumi Takemoto; Charlly Kao; Arnob Banerjee; Felix Schambach; John K Northrop; Hao Shen; E John Wherry; Steven L Reiner
Journal:  J Exp Med       Date:  2007-08-13       Impact factor: 14.307

Review 10.  Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.

Authors:  Laura Papagno; Celsa A Spina; Arnaud Marchant; Mariolina Salio; Nathalie Rufer; Susan Little; Tao Dong; Gillian Chesney; Anele Waters; Philippa Easterbrook; P Rod Dunbar; Dawn Shepherd; Vincenzo Cerundolo; Vincent Emery; Paul Griffiths; Christopher Conlon; Andrew J McMichael; Douglas D Richman; Sarah L Rowland-Jones; Victor Appay
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

View more
  11 in total

1.  Alterations in high-dimensional T-cell profile and gene signature of immune aging in HIV-infected older adults without viremia.

Authors:  Min Sun Shin; Hong-Jai Park; Syim Salahuddin; Ruth R Montgomery; Brinda Emu; Albert C Shaw; Insoo Kang
Journal:  Aging Cell       Date:  2022-08-29       Impact factor: 11.005

2.  Characterization of eomesodermin and T-bet expression by allostimulated CD8+ T cells of healthy volunteers and kidney transplant patients in relation to graft outcome.

Authors:  A Perez-Gutierrez; D M Metes; L Lu; S Hariharan; A W Thomson; M B Ezzelarab
Journal:  Clin Exp Immunol       Date:  2018-09-23       Impact factor: 4.330

Review 3.  Adaptive Memory of Human NK-like CD8+ T-Cells to Aging, and Viral and Tumor Antigens.

Authors:  María Luisa Pita-López; Alejandra Pera; Rafael Solana
Journal:  Front Immunol       Date:  2016-12-19       Impact factor: 7.561

4.  Assessing the role of the T-box transcription factor Eomes in B cell differentiation during either Th1 or Th2 cell-biased responses.

Authors:  Lucy Cooper; Lauren Hailes; Amania Sheikh; Colby Zaph; Gabrielle T Belz; Joanna R Groom; Kim L Good-Jacobson
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

5.  An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression.

Authors:  Federico Perdomo-Celis; Paula A Velilla; Natalia A Taborda; María Teresa Rugeles
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

6.  HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Authors:  Tinashe E Nyanhete; Alyse L Frisbee; Todd Bradley; William J Faison; Elizabeth Robins; Tamika Payne; Stephanie A Freel; Sheetal Sawant; Kent J Weinhold; Kevin Wiehe; Barton F Haynes; Guido Ferrari; Qi-Jing Li; M Anthony Moody; Georgia D Tomaras
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

7.  Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy.

Authors:  Sara De Biasi; Lara Gibellini; Domenico Lo Tartaro; Simone Puccio; Claudio Rabacchi; Emilia M C Mazza; Jolanda Brummelman; Brandon Williams; Kelly Kaihara; Mattia Forcato; Silvio Bicciato; Marcello Pinti; Roberta Depenni; Roberto Sabbatini; Caterina Longo; Massimo Dominici; Giovanni Pellacani; Enrico Lugli; Andrea Cossarizza
Journal:  Nat Commun       Date:  2021-03-15       Impact factor: 14.919

8.  Continuous Effector CD8(+) T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population.

Authors:  H Hamlet Chu; Shiao-Wei Chan; John Paul Gosling; Nicolas Blanchard; Alexandra Tsitsiklis; Grant Lythe; Nilabh Shastri; Carmen Molina-París; Ellen A Robey
Journal:  Immunity       Date:  2016-07-12       Impact factor: 31.745

9.  The T cell differentiation landscape is shaped by tumour mutations in lung cancer.

Authors:  Ehsan Ghorani; James L Reading; Jake Y Henry; Marc Robert de Massy; Rachel Rosenthal; Virginia Turati; Kroopa Joshi; Andrew J S Furness; Assma Ben Aissa; Sunil Kumar Saini; Sofie Ramskov; Andrew Georgiou; Mariana Werner Sunderland; Yien Ning Sophia Wong; Maria Vila De Mucha; William Day; Felipe Galvez-Cancino; Pablo D Becker; Imran Uddin; Theres Oakes; Mazlina Ismail; Tahel Ronel; Annemarie Woolston; Mariam Jamal-Hanjani; Selvaraju Veeriah; Nicolai J Birkbak; Gareth A Wilson; Kevin Litchfield; Lucia Conde; José Afonso Guerra-Assunção; Kevin Blighe; Dhruva Biswas; Roberto Salgado; Tom Lund; Maise Al Bakir; David A Moore; Crispin T Hiley; Sherene Loi; Yuxin Sun; Yinyin Yuan; Khalid AbdulJabbar; Samra Turajilic; Javier Herrero; Tariq Enver; Sine R Hadrup; Allan Hackshaw; Karl S Peggs; Nicholas McGranahan; Benny Chain; Charles Swanton; Sergio A Quezada
Journal:  Nat Cancer       Date:  2020-05-22

Review 10.  How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.

Authors:  Jonathan Z Li; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.